admedicum

04/09/2026

🧪 We’d like to share information about the HERCULES clinical study, which is evaluating a once daily formulation of mexiletine prolonged release (PR) for people living with Myotonic Dystrophy Type 1 or Type 2.

This may be of interest to individuals affected by muscle stiffness and delayed relaxation (myotonia). The study is being conducted by Lupin Atlantis Holdings SA.

👉More information can be found on the official study website: https://www.MyotonicDystrophyStudy.com

Have you been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2)?​ Have you been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2)? Learn more about clinical research studies evaluating if mexiletine prolonged release (PR) is safe and effective in alleviating muscle stiffn...

21/05/2026

We are proud to launch our new website today!

As we celebrate our 10th anniversary this year, we are reflecting on a decade of actively shaping patient engagement. This is highlighted through monthly features that showcase our key achievements. Our new website reflects not only what we do, but also how we do it and who we are: an intrinsically motivated, international and empathetic team that combines patient advocacy with industry expertise to create meaningful impact where it matters most.

Our mission has always been to facilitate meaningful collaboration between people living with a disease, industry, and other healthcare stakeholders.
With this relaunch, we have translated that mission into a clearer structure by organising our services across departments and introducing concrete tools that enable practical, patient-driven, tailored solutions.

Looking ahead, we are eager to continue advancing our vision and working with all of you on new, impactful projects — always with patients.

We wholeheartedly invite you to explore our new website: www.admedicum.com.

29/01/2026

As we approach our 10th anniversary on June 10, 2026, we continue to celebrate the people, projects, and partnerships that have shaped our journey in patient engagement and access.

Each month, we’re counting down and featuring one inspiring project that reflects our mission and values.

This month’s story highlights the growing importance of European Patient Advocacy, showcasing how collaboration across borders can strengthen patient voices and accelerate meaningful change.

A compelling example is the European Myasthenia Gravis Summit (EUMGS), an initiative driven by EuMGA, to bring together local MG patient advocacy groups from across Europe to learn from one another, align on shared priorities, and become stronger together.

Join us on this journey as we look back at some of the most important moments that shaped us.

https://admedicum.com/european-patient-advocacy-uniting-local-pags-to-be-stronger-together/

09/09/2025

Did you know that admedicum will celebrate its 10th anniversary on June 10, 2026?

To acknowledge this milestone, we’re launching a special campaign to celebrate, recognize and say thank you for 10 incredible years of driving meaningful patient engagement and access together with so many impactful people and organisations.

Each month, we’ll countdown and feature one inspiring project that reflects our mission and values.

This month’s highlight: The Power of Information from Patients for Patients – SMAlltalk, initiated and fully funded by BioGenes GmbH, a platform that connects people living with Spinal Muscular Atrophy (SMA) and their loved ones. https://admedicum.com/the-power-of-information-from-patients-for-patients/

Join us on this journey as we look back at some of the most important moments that shaped us.

hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Clinical programmes live or die by the quality of their evidence. In‑Trial Interviews (ITIs) capture unfiltered patient insight—before, during and after dosing—so you can de‑risk endpoints, strengthen HTA dossiers and keep participants engaged.

24/02/2025

Raising the Voice of NTM-PD Patients – ENPADE Survey Findings Published

We are proud to share that the results of the European NTM Pulmonary Disease Patient Disease Experience Survey (ENPADE) have now been published in BMC Pulmonary Medicine: Read the paper. A summary report is also available: www.ntmpatientsurvey.eu.

Living with non-tuberculous mycobacteria pulmonary disease (NTM-PD) presents many challenges and the burden of disease is substantial. Until now, patient experience data on NTM-PD has been limited.

The ENPADE survey, conducted across eight European countries, gathered input from 543 NTM-PD patients and provided valuable patient insights into:
✔ How NTM-PD affects patients’ daily lives and activities
✔ The burden of disease and unmet needs
✔ Barriers to accessing medical care and gaps in healthcare

We find it most important that the voices of patients are heard and recognized in decision-making processes, ensuring that healthcare advances in a way that matters most to patients.

Our sincere thanks to all participants for their time and willingness to share their experiences.

12/02/2025

You can also follow on Instagram to see more.

10/02/2025

Aiutate i ricercatori a capire l'impatto quotidiano della bronchiectasie da fibrosi non cistica senza fibrosi cistica (NCFBE). Stanno cercando adulti che vivono con la bronchiectasia (senza fibrosi cistica), nota anche come NCFBE, e i loro familiari per rispondere a un sondaggio online. Le sue risposte possono favorire il cambiamento e aumentare la consapevolezza. Se conosce una persona che attualmente soffre e sostiene i sintomi della NCFBE e che ha avuto almeno una riacutizzazione (esacerbazione) della bronchiectasia nell'ultimo anno, potrebbe essere idoneo. Si impegni ora per contribuire a una migliore comprensione della bronchiectasie.

03/12/2024

Join us for Patient Engagement Networking in Paris on January 22, 2025
More details and link to register:

Passez un moment convivial et faites des rencontres inspirantes dans le cadre magnifique de la Cité Internationale Universitaire !